Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Zoster vaccine live.

Denise R Kockler1, Michelle W McCarthy

  • 1Drug Information Services, Virginia Commonwealth University Health System-Medical College of Virginia Hospitals, and the Virginia Commonwealth University School of Pharmacy, Charlottesville, Virginia 23298-0042, USA. dkockler@mcvh-vcu.edu

Pharmacotherapy
|June 28, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Improving Pediatric Adverse Drug Event Reporting through Clinical Pharmacy Services.

The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG·2012
Same author

Belimumab: a BLyS-specific inhibitor for systemic lupus erythematosus.

The Annals of pharmacotherapy·2010
Same author

Plerixafor: a peripheral blood stem cell mobilizer.

Pharmacotherapy·2010
Same author

Probiotics for maintaining remission of ulcerative colitis in adults.

The Annals of pharmacotherapy·2010
Same author

Aromatase inhibitors for ovulation and pregnancy in polycystic ovary syndrome.

The Annals of pharmacotherapy·2009
Same author

Erythropoiesis-stimulating agents: creation and validation of a computerized prescriber order entry alert.

The Annals of pharmacotherapy·2009

The Shingles Prevention Study shows that the Zoster vaccine live significantly reduces illness, pain, and postherpetic neuralgia in older adults. Universal vaccination is now recommended for individuals aged 60 and above.

Area of Science:

  • Immunology
  • Virology
  • Geriatrics

Background:

  • Herpes zoster (shingles) is a neurocutaneous disease caused by the varicella-zoster virus.
  • It leads to significant morbidity and long-term complications, particularly in older adults.
  • Previous treatments focused on symptom management rather than prevention.

Purpose of the Study:

  • To evaluate the efficacy of Zoster vaccine live in preventing herpes zoster and its complications.
  • To assess the safety and tolerability of the vaccine in the target population.

Main Methods:

  • The Shingles Prevention Study involved administering Zoster vaccine live to adults aged 60 years and older.
  • Efficacy endpoints included the incidence of herpes zoster, herpes zoster pain, and postherpetic neuralgia.

Related Experiment Videos

  • Adverse events were monitored and compared between vaccine and placebo recipients.

    • Main Results:

    • Zoster vaccine live reduced the overall burden of herpes zoster illness by 61.1%.
    • It decreased the frequency of pain and discomfort by 51.3% and postherpetic neuralgia by 66.5%.
    • Adverse events were generally mild, with injection site reactions and headache being more frequent in vaccine recipients.

    Conclusions:

    • Zoster vaccine live is effective in preventing herpes zoster and its associated complications in older adults.
    • The vaccine is well-tolerated, with mild adverse events.
    • Universal vaccination is recommended for individuals 60 years and older, including those with prior shingles episodes.